Trastuzumab, a recombinant monoclonal antibody, acts against HER2 receptors. Design: In this international randomized trial, women who had undergone surgical excision of a HER2-positive, early ...

Combination of lapatinib and trastuzumab shrinks HER2 positive breast cancer significantly in 11 days after diagnosis Date: March 10, 2016 Source: The European CanCer Organisation (ECCO) Summary ...

The HER2-targeting monoclonal antibody trastuzumab, in combination with chemotherapy, improves response rates in metastatic breast cancer patients with tumors overexpressing HER2; however ...